SCHEMBL5540255

SCHEMBL5540255

[CH2]c1cccc(-c2ccccc2C(F)(F)F)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 7/20 0.53
AR P10275 1/20 0.50
TRPA1 O75762 3/20 0.45
BACE1 P56817 1/20 0.45
TRPM8 Q7Z2W7 1/20 0.45
SCN10A Q9Y5Y9 1/20 0.42
HSD11B1 P28845 1/20 0.41
GRM5 P41594 1/20 0.41
NOTUM Q6P988 1/20 0.41
PIK3R1 P27986 1/20 0.40
PIK3CA P42336 1/20 0.40
USP2 O75604 1/20 0.40
ALDH1A1 P00352 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
TSHR P16473 1/20 0.40
MAPK1 P28482 1/20 0.40
CYP2C19 P33261 1/20 0.40
CLK4 Q9HAZ1 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30146607 0.81 SCN9A (0.59) SCN9AARTRPA1BACE1TRPM8
SCHEMBL5112656 0.79 SCN9A (0.54) SCN9AARTRPA1BACE1TRPM8
SCHEMBL2097564 0.79 AR (0.50) SCN9AARTRPA1BACE1TRPM8
SCHEMBL3398486 0.78 SCN9A (0.53) SCN9AARTRPA1BACE1TRPM8
SCHEMBL1027860 0.78 SCN9A (0.53) SCN9AARTRPA1BACE1TRPM8
SCHEMBL5540262 0.78 SCN9A (0.53) SCN9AARTRPA1BACE1TRPM8
SCHEMBL3833481 0.78 SCN9A (0.53) SCN9AARTRPA1BACE1TRPM8
SCHEMBL14013706 0.78 SCN9A (0.53) SCN9AARTRPA1BACE1TRPM8
SCHEMBL28759695 0.78 SCN9A (0.53) SCN9AARTRPA1BACE1TRPM8
SCHEMBL163729 0.78 HSD11B1 (0.55) SCN9AARTRPA1BACE1TRPM8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 SCN9A 3612/4885AR 254/4885TRPA1 3038/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.